Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …

Objective To compare effectiveness and safety of warfarin and the direct oral anticoagulants
(DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine …

Background Most observational studies on direct oral anticoagulants (DOACs) used single
data sources with limited generalizability. This ARISTOPHANES (Anticoagulants for …

Background: The efficacy and safety of novel oral anticoagulants (NOACs) as alternatives to
warfarin therapy in nonvalvular atrial fibrillation (NVAF) patients have been studied in …

Objective: To conduct a systematic literature review (SLR) and network meta-analysis (NMA)
of real-world studies comparing major bleeding risk among patients with non-valvular atrial …

Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …

Background Limited data are available about the real‐world safety of non‐vitamin K
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …

Introduction There are a paucity of real-world data examining effectiveness and safety of non-
vitamin K antagonist oral anticoagulants (NOACs) and warfarin in nonvalvular atrial …

Background and Purpose: The effects of direct oral anticoagulants in nonvalvular atrial
fibrillation should be assessed in actual conditions of use. France has near-universal …